Nya data för Siponimod presenterade på AAN

Nya data för Siponimod presenterade på AAN
Novartis presenterade idag en ny analys av data från EXPAND studien där Siponimod testats på patienter med sekundär, progressiv multipel skleros.

*Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis (SPMS)[1]
*In EXPAND, siponimod also had a meaningful benefit on patients’ cognitive processing speed[2]
*Findings add to clinical evidence for siponimod in SPMS, an area with a high unmet need for well-tolerated and effective new therapies[3]

Novartis today announced new analyses from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in patients with secondary progressive multiple sclerosis (SPMS). In pre-specified statistical analyses, treatment with siponimod consistently reduced the risk of confirmed disability progression in SPMS patients, with and without relapses[1]. In addition, new post-hoc analyses using more accurate methods to estimate the treatment effect on disability progression, now substantiate that the risk reduction with siponimod is largely disassociated from relapses. Siponimod also showed a significant benefit on cognitive processing speed, the key cognitive function impacted by MS, which frequently deteriorates in people with the disease[2]. These results are being presented at the 70th American Academy of Neurology (AAN) Annual Meeting, in Los Angeles, USA, April 21-27, 2018.

As previously reported for the overall study population, treatment with siponimod resulted in a statistically significant risk reduction in disability progression sustained for three- and six-months[4]. The new EXPAND study analyses, using a more advanced model-based approach, show an estimated risk reduction for disability progression, sustained at three-months that ranged from 14-20% compared to placebo (calculated by principal stratum analysis) for non-relapsing patients. For disability sustained at six-months, estimated risk reduction was even greater, spanning from 29-33%. Other complementary statistical approaches[1] assessing the effect of siponimod on disability progression disassociated from relapses showed consistent results.

”Siponimod’s beneficial effect on preventing disability progression, independent from its reduction in relapse frequency, demonstrates that patients with secondary progressive MS could benefit from this treatment,” said study steering committee member Bruce Cree, MD, PhD, MAS, Clinical Research Director and Associate Professor, University of California, San Francisco, School of Medicine. ”This is very exciting because many people diagnosed with relapsing-remitting MS, the most common form of the disease, will ultimately transition to SPMS, where without effective new therapies, they experience gradual worsening of disability despite infrequent relapses.”

In pre-specified and post hoc analyses, siponimod’s effect on cognitive processing speed was evaluated, as measured by the Symbol Digit Modalities Test (SDMT). SDMT is the only cognitive test with established clinical relevance of change in MS and is widely accepted by patients and physicians[5]. Other tests included the Paced Auditory Serial Addition Test (PASAT, assessing cognitive processing speed) and the Brief Visuospatial Memory Test-Revised (BVMT-R, assessing memory)[6],[7]. From baseline to month 24, treatment with siponimod showed a significant benefit on cognitive processing speed, compared to placebo, for all patients (SDMT, p=0.0004), and also in those who had relapses within two years before starting the trial (SDMT p=0.0151; PASAT p=0.0275) and those who did not (SDMT p=0.0099; PASAT not statistically significant)[2]. Treatment with siponimod did not result in significant differences in memory (BVMT-R)[2].

”A decline in the ability to rapidly process information affects more than half of MS patients and is more severe in secondary progressive MS than relapsing-remitting MS. These data show that siponimod could have a meaningful impact on these patients’ daily lives,” said Danny Bar-Zohar, Global Head Neuroscience Development, Novartis. ”Furthermore, the advanced models used in the new analyses help us to better understand the relationship between relapses and disability and the effect of siponimod on these parameters. We are encouraged by these latest findings, which further solidify the clinical evidence for siponimod as a potential new, much needed treatment option for SPMS.”

Novartis has initiated the submission of siponimod for US approval in SPMS in the first half of 2018. Filing for EU approval is planned to follow later in 2018.

About the EXPAND study
The EXPAND study is a randomized, double-blind, placebo-controlled Phase III study, comparing the efficacy and safety of siponimod versus placebo in people with secondary progressive MS (SPMS)[4],[8]. It is the largest randomized, controlled study in SPMS to date, and included 1,651 people with SPMS from 31 countries[4],[9]. At the time of the study, individuals enrolled in EXPAND had a mean age of 48 years and had been living with MS for approximately 17 years[4]. Patients had received a diagnosis of SPMS, and also demonstrated progression of disability in the two years prior to study[4],[8]. They also had an Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5 inclusive, with a median score of 6.0, which corresponds to the use of a unilateral walking aid (e.g., a cane or a crutch)[4],[8]. Patients were randomized to receive either 2mg siponimod once-daily or placebo, in a 2:1 ratio[4],[8]. Patients continued on siponimod treatment in the open-label long-term extension part of the study[4].

About siponimod (BAF312)
Siponimod is an investigational, selective modulator of specific subtypes of the sphingosine-1-phosphate (S1P) receptor[10]. Siponimod binds to the S1P1 sub-receptor on lymphocytes, which prevents them from entering the central nervous system (CNS) of patients with multiple sclerosis and is believed to contribute to the anti-inflammatory effects of siponimod[11],[12].

Siponimod also enters the CNS and binds to the S1P5 sub-receptor on specific cells in the CNS (oligodendrocytes and astrocytes)[13]. By binding to these specific receptors, siponimod has the potential to modulate damaging cell activity and may help to reduce the loss of neurological function associated with SPMS[13]-[15]. The receptor specificity and pharmacokinetic properties of siponimod facilitate treatment initiation, and contribute to its safety and convenience profile[10].

[1] Cree B, Fox R, Giovannoni G, et al. Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study. Abstract no. 005. Oral presentation at the 70th Annual Meeting of the American Academy of Neurology, Los Angeles, CA, April 21-27, 2018.
[2] Benedict R, Cree B, Tomic D, et al. Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase III EXPAND Study. Abstract no. 004. Oral presentation at the 70th Annual Meeting of the American Academy of Neurology, Los Angeles, CA, April 21-27, 2018.
[3] Mehr SR and Zimmerman MP. Reviewing the unmet needs of patients with multiple sclerosis. Am Health Drug Benefits. 2015; 8(6); 426-431.
[4] Kappos L et al. Siponimod versus placebo in secondary progressive multiple sclerosis: a double-blinded randomized, phase 3 study. The Lancet. 2018; 31;391(10127): 1263-1273.
[5] Benedict RHB et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler Journal. 2017; 23(5): 721-733.
[6] Drake AS et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010; 16(2): 228-237.
[7] Tam JW, Schmitter-Edgecombe M. The role of processing speed in the brief visuospatial memory test – revised. Clin Neuropsychol. 2013; 27(6): 962-972.
[8] ClinicalTrials.gov. Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND). https://clinicaltrials.gov/ct2/show/NCT01665144?term=BAF312+expand&rank=1. Accessed April 2018.
[9] Kappos L et al. Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084). Neurology. 2016; 86(16): suppl. P3.084.
[10] Gergely P et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012; 167(5): 1035-47.
[11] Brinkmann V, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9(11): 883-97.
[12] Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33(2): 91-101.
[13] Tavares A et al. Brain distribution of MS565, an imaging analogue of siponimod (BAF312), in non-human primates. Neurology. 2014; 82(10): suppl. P1.168.
[14] Aslanis V et al. Siponimod (BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter areas. Mult Scler J. 2012; 18(10): suppl. P792.
[15] Brana C et al. Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2014; 40(5): 564-78.
[16] PubMed Health. Multiple Sclerosis (MS). https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024311/. Accessed April 2018.
[17] Multiple Sclerosis Society. Types of MS. https://www.mssociety.org.uk/what-is-ms/types-of-ms. Accessed April 2018.
[18] MS Society. Secondary Progressive MS (SPMS). https://www.mssociety.org.uk/what-is-ms/types-of-ms/secondary-progressive-spms. Accessed April 2018.
[19] Multiple Sclerosis International Federation. Atlas of MS 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed April 2018.
[20] Tremlett H, et al. The natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008; 14: 314-324